Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors

20 Sept 2022

Abstract excerpt

With the addition of the compstatin-based complement C3 inhibitor pegcetacoplan, another class of complement targeted therapeutics have recently been approved. Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/AMY-101). Despite this progress, the target binding and inhibitory modes of the compstatin family remain incompletely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Complement system in diseases
Share to Peripheral Neuropathies and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36127336
DOI: 10.1038/s41467-022-33003-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitorsPMID 36127336Read ↗

Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside interventionSemantic proximity Read ↗

Compstatins: the dawn of clinical C3-targeted complement inhibitionSemantic proximity Read ↗

Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3.Semantic proximity Read ↗

A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug interventionSemantic proximity Read ↗

Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity.Semantic proximity Read ↗

First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitorSemantic proximity Read ↗

Structural studies offer a framework for understanding the role of properdin in the alternative pathway and beyondSemantic proximity Read ↗

A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivativesSemantic proximity Read ↗

Structural insight into proteolytic activation and regulation of the complement system.Semantic proximity Read ↗

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.Semantic proximity Read ↗

Structure of the Tyrosine-sulfated C5a Receptor N Terminus in Complex with Chemotaxis Inhibitory Protein of Staphylococcus aureusSemantic proximity Read ↗

Leveraging Fungal Calcineurin-Inhibitor Structures, Biophysics and Dynamics to Design Selective and Non-Immunosuppressive FK506 AnalogsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.